Q4 & FY22 Highlights
Management Commentary
on
results
Commenting
the
announcement, (Hony) Brig. Dr. Arvind
Lal, Executive Chairman said:
"India remains a largely underserved market
for diagnostics. The scope for growth for
companies like ours is huge and we want to
leverage our position as a leading player. At Dr.
Lal PathLabs, we see ourselves as a progressive
brand and have been at the forefront of
integrating technology into our business model.
This helps us reduce costs as well as provide a
more seamless and cohesive experience to our
patients. We continue to invest in latest
technologies across medical science and
patient service in line with out vision of being
the most trusted healthcare partner"
Commenting
announcement,
on
Dr. Om
Managing Director said:
the
results
Manchanda,
"The acquisition of Suburban Diagnostics has
brought Dr. Lal PathLabs brand to the heart of
Western market i.e., Maharashtra. And we will
work with the Suburban team to leverage the
joint expertise and capabilities to create best-
in-class proposition and deliver top notch
patient experience.
We have demonstrated strong growth in this
quarter, which is likely to continue as we realise
our growth aspirations in various regions
across the country. With one of the strongest
digital presence in the Indian diagnostics and
healthcare industry, we are well placed to
reach more patients and offer them accurate
diagnostics at affordable costs."
"
on
results
Commenting
the
announcement, Mr. Bharath Uppiliappan,
Chief Executive Officer said:
"Q4 FY22 started off well, however, the onset
of Omicron wave in early part of the quarter
impacted Non Covid business which recovered
only in second half of the quarter. Our strategic
initiatives leveraging digital on patient service
levels, geography/tests expansion and channel
capability building continue to make good
strides. This will enable us to maintain our
leadership position for the times to come"
31
Dr Lal PathLabsView entire presentation